Sobi to list bond loan on NASDAQ OMX Stockholm and publishes
STOCKHOLM, SWEDEN -- (Marketwire) -- 11/12/12 -- On 26 June 2012
Swedish Orphan Biovitrum AB (Sobi) issued a 5-year senior unsecured
bond loan in the total amount of SEK 600 million. Sobi has applied
for a listing of the bond loan on NASDAQ OMX Stockholm in accordance
with the terms
and conditions of the bond loan and prepared a
The prospectus has been approved by the Swedish Financial Supervisory
and the bond loan is expected to be listed on NASDAQ OMX
Stockholm on 16 November 2012. The prospectus is now available on
Sobi's webpage http://www.sobi.com/Investors--Media/Bond-Loan/
Swedish Orphan Biovitrum (Sobi)
Sobi is an international healthcare company dedicated to bringing
therapies and services to improve the lives of rare
disease patients. The product portfolio is primarily focused on
inflammation and genetic diseases,
with three late stage biological
development projects within hemophilia and neonatology. Sobi also
markets more than 40 products for companies in the specialty and rare
disease space. In 2011, Sobi had revenues of SEK 1.9 billion
around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.
information above has been published pursuant to the Swedish
Securities Market Act and/or the Financial Instruments Trading Act.
The information was
released for public distribution on 12 November,
2012 at 12:45 p.m. CET.
Sobi Press Release on November 12, 2012 in
pdf format: http://hugin.info/134557/R/1657011/535846.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
For further information, please contact:
Vice President, Head of Communications and Investor Relations (Interim)
Tel.: +46 8 697 21 88
Press spacebar to pause and continue. Press esc to stop.